These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 36837928)
61. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238 [TBL] [Abstract][Full Text] [Related]
62. β-d-N Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332 [TBL] [Abstract][Full Text] [Related]
63. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters. Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401 [TBL] [Abstract][Full Text] [Related]
64. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339 [TBL] [Abstract][Full Text] [Related]
65. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design. Shehzadi K; Yu M; Liang J Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139312 [TBL] [Abstract][Full Text] [Related]
66. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. Reçber T; Timur SS; Erdoğan Kablan S; Yalçın F; Karabulut TC; Neslihan Gürsoy R; Eroğlu H; Kır S; Nemutlu E J Pharm Biomed Anal; 2022 May; 214():114693. PubMed ID: 35276385 [TBL] [Abstract][Full Text] [Related]
67. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19. Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK bioRxiv; 2022 Feb; ():. PubMed ID: 35169793 [TBL] [Abstract][Full Text] [Related]
72. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19. Atmar RL; Finch N Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759 [TBL] [Abstract][Full Text] [Related]
73. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals. Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914 [TBL] [Abstract][Full Text] [Related]